HOB Biotech Group Corp Ltd (688656) - Net Assets
Based on the latest financial reports, HOB Biotech Group Corp Ltd (688656) has net assets worth CN¥826.70 Million CNY (≈ $120.97 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥912.83 Million ≈ $133.58 Million USD) and total liabilities (CN¥86.13 Million ≈ $12.60 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 688656 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥826.70 Million |
| % of Total Assets | 90.56% |
| Annual Growth Rate | 34.56% |
| 5-Year Change | 6.49% |
| 10-Year Change | N/A |
| Growth Volatility | 82.42 |
HOB Biotech Group Corp Ltd - Net Assets Trend (2016–2025)
This chart illustrates how HOB Biotech Group Corp Ltd's net assets have evolved over time, based on quarterly financial data. See HOB Biotech Group Corp Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for HOB Biotech Group Corp Ltd (2016–2025)
The table below shows the annual net assets of HOB Biotech Group Corp Ltd from 2016 to 2025. For live valuation and market cap data, see HOB Biotech Group Corp Ltd (688656) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥820.01 Million ≈ $119.99 Million |
+0.97% |
| 2024-12-31 | CN¥812.14 Million ≈ $118.84 Million |
+0.17% |
| 2023-12-31 | CN¥810.73 Million ≈ $118.64 Million |
+4.00% |
| 2022-12-31 | CN¥779.57 Million ≈ $114.08 Million |
+1.24% |
| 2021-12-31 | CN¥770.00 Million ≈ $112.68 Million |
+273.09% |
| 2020-12-31 | CN¥206.39 Million ≈ $30.20 Million |
+37.93% |
| 2019-12-31 | CN¥149.64 Million ≈ $21.90 Million |
+12.41% |
| 2018-12-31 | CN¥133.12 Million ≈ $19.48 Million |
+68.45% |
| 2017-12-31 | CN¥79.03 Million ≈ $11.56 Million |
+39.35% |
| 2016-12-31 | CN¥56.71 Million ≈ $8.30 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to HOB Biotech Group Corp Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 912.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥178.55 Million | 21.77% |
| Common Stock | CN¥63.48 Million | 7.74% |
| Other Components | CN¥577.98 Million | 70.48% |
| Total Equity | CN¥820.01 Million | 100.00% |
HOB Biotech Group Corp Ltd Competitors by Market Cap
The table below lists competitors of HOB Biotech Group Corp Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DBV Technologies S.A.
PA:DBV
|
$979.74 Million |
|
Amerant Bancorp Inc.
NYSE:AMTB
|
$979.96 Million |
|
Shandong Bohui Paper Industry Co Ltd
SHG:600966
|
$980.07 Million |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
$980.08 Million |
|
MetroCity Bankshares
NASDAQ:MCBS
|
$979.31 Million |
|
Plymouth Industrial REIT Inc
NYSE:PLYM
|
$979.23 Million |
|
AcadeMedia AB (publ)
ST:ACAD
|
$979.06 Million |
|
ScanSource Inc
NASDAQ:SCSC
|
$978.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in HOB Biotech Group Corp Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 812,137,037 to 820,008,631, a change of 7,871,594 (1.0%).
- Net income of 23,200,785 contributed positively to equity growth.
- Dividend payments of 20,791,199 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥23.20 Million | +2.83% |
| Dividends Paid | CN¥20.79 Million | -2.54% |
| Other Changes | CN¥5.46 Million | +0.67% |
| Total Change | CN¥- | 0.97% |
Book Value vs Market Value Analysis
This analysis compares HOB Biotech Group Corp Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.14x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 84.48x to 8.14x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥1.25 | CN¥105.45 | x |
| 2017-12-31 | CN¥1.74 | CN¥105.45 | x |
| 2018-12-31 | CN¥2.92 | CN¥105.45 | x |
| 2019-12-31 | CN¥3.16 | CN¥105.45 | x |
| 2020-12-31 | CN¥4.37 | CN¥105.45 | x |
| 2021-12-31 | CN¥12.51 | CN¥105.45 | x |
| 2022-12-31 | CN¥12.35 | CN¥105.45 | x |
| 2023-12-31 | CN¥12.68 | CN¥105.45 | x |
| 2024-12-31 | CN¥12.80 | CN¥105.45 | x |
| 2025-12-31 | CN¥12.96 | CN¥105.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently HOB Biotech Group Corp Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.83%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.82%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.14x
- Recent ROE (2.83%) is below the historical average (16.47%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 7.64% | 3.88% | 0.90x | 2.20x | CN¥-1.34 Million |
| 2017 | 27.02% | 14.59% | 1.01x | 1.82x | CN¥13.45 Million |
| 2018 | 30.16% | 19.93% | 0.89x | 1.69x | CN¥26.84 Million |
| 2019 | 42.66% | 24.64% | 0.92x | 1.89x | CN¥48.87 Million |
| 2020 | 27.43% | 25.52% | 0.75x | 1.44x | CN¥35.98 Million |
| 2021 | 11.19% | 27.13% | 0.37x | 1.12x | CN¥9.19 Million |
| 2022 | 5.34% | 13.00% | 0.34x | 1.21x | CN¥-36.31 Million |
| 2023 | 5.84% | 12.00% | 0.42x | 1.17x | CN¥-33.74 Million |
| 2024 | 4.53% | 9.15% | 0.39x | 1.27x | CN¥-44.41 Million |
| 2025 | 2.83% | 5.82% | 0.43x | 1.14x | CN¥-58.80 Million |
Industry Comparison
This section compares HOB Biotech Group Corp Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $3,442,122,104
- Average return on equity (ROE) among peers: 12.05%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| HOB Biotech Group Corp Ltd (688656) | CN¥826.70 Million | 7.64% | 0.10x | $979.53 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $4.98 Billion | -4.70% | 0.37x | $371.06 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $2.13 Billion | 17.09% | 0.37x | $3.63 Billion |
| Double Medical Technology Inc (002901) | $3.11 Billion | 2.98% | 0.27x | $2.56 Billion |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $6.77 Billion | 62.15% | 0.36x | $506.97 Million |
| Lepu Medical Tech Beijing (300003) | $10.54 Billion | 17.10% | 0.73x | $3.19 Billion |
| INKON Life Technology Co Ltd (300143) | $343.97 Million | 0.00% | 1.34x | $764.39 Million |
| Edan Instruments Inc (300206) | $1.25 Billion | 3.50% | 0.14x | $1.15 Billion |
| Guangdong Biolight Meditech Co Ltd (300246) | $1.39 Billion | -4.69% | 0.82x | $735.30 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $761.02 Million | 12.92% | 0.49x | $467.29 Million |
| Sinocare Inc (300298) | $3.14 Billion | 14.20% | 0.47x | $1.17 Billion |
About HOB Biotech Group Corp Ltd
HOB Biotech Group Corp.,Ltd. operates as an in vitro diagnostic company in China and internationally. It provides diagnostic tools, such as line immune, enzyme-linked immunosorbent, and chemiluminescent paramagnetic microparticle immune assays to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care. HOB Biotech Group Corp.,Ltd was founded in 2009 and is ba… Read more